Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
Healthcare
$4.44 -1.17%
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
52W Low $5.50High $9.63
Volume 0.01M
Average 0.01M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$7.39M
FY 2025 · Annual
Investing Cash Flow
-$389,000.00
FY 2025 · Annual
Financing Cash Flow
$170,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | 334K | 548K | (5.34M) | (7.28M) | 4.7M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| Deferred Income Tax | 49K | 0 | 1M | 0 | 0 |
| Stock-Based Compensation | 598K | 912K | 864K | 1.12M | 654K |
| Change in Working Capital | (4.17M) | 2.34M | 4.23M | (3.82M) | (621K) |
| Accounts Receivables | (2.27M) | (2.82M) | 1.31M | (1.99M) | (1.44M) |
| Inventory | (1.1M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.25M) | 974K | 2.47M | 465K | (1.75M) |
| Other Working Capital | 441K | 4.18M | 470K | (2.3M) | 2.56M |
| Other Non-Cash Items | 323K | 1.07M | 952K | 1.98M | 1.01M |
| Operating Cash Flow | (1.68M) | 6.5M | 3.96M | (6.14M) | 7.39M |
| Capital Expenditures | (3.28M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.17M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Debt Repayment | (174K) | 0 | 0 | (146K) | (150K) |
| Common Stock Issued | 1.37M | 207K | 85K | 253K | 320K |
| Common Stock Repurchased | 0 | 0 | (74K) | (634K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 85K | 253K | 0 |
| Financing Cash Flow | 1.2M | 207K | 11K | (527K) | 170K |
| Effect of Forex Changes | 0 | 0 | 17K | 0 | 0 |
| Net Change in Cash | (3.66M) | 4.32M | 1.11M | (7.5M) | 7.17M |
| Free Cash Flow | (4.96M) | 4.11M | 1.08M | (6.97M) | 7M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$4.7M
+ D&A$1.6M
+ Stock-Based Comp$654.0K
+ Deferred Tax$0
- Working Capital-$621.0K
+ Other Non-Cash$1.0M
= Operating Cash Flow$7.4M
- Capex-$389.0K
= Free Cash Flow$7.0M
Analysis
FY2025 free cash flow is $7.0M. FCF conversion is 148.8% of net income. Operating cash flow was $7.4M, with capex of -$389.0K. The largest bridge item is D&A at $1.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 8-K | Current report | Oct 16, 2026 |
Does CSBR generate free cash flow?
Champions Oncology, Inc. (CSBR) generated $7.00M of free cash flow in fiscal 2025.
How much operating cash flow does CSBR produce?
Operating cash flow was $7.39M, before capital expenditures of $389,000.00.
Continue the stock analysis
Jump to another research area for this company.